🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 62 of 757 · Phase 3 first, then by program name

  1. Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Gilead Sciences International Limited

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  2. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Revlimid 25 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Oxaliplatin 5mg/ml Concentrate for Solution for Infusion, Revlimid 5 mg hard capsules, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Truxima 500 mg concentrate for solution for infusion, Revlimid 20 mg hard capsules, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  3. Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    phase 3 small molecule active

    1 trial

  4. Gemcitabine,Cisplatin

    China SXT Pharmaceuticals

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  5. Generic Budesonide/Formoterol Fumarate Dihydrate

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

  6. Generic Estradiol Vaginal Cream USP, 0.01%

    Teva Pharma GmbH

    Atrophic Vaginitis

    phase 3 small molecule completed

    1 trial

  7. Generic Ivermectin Lotion 0.5%

    Teva Pharma GmbH

    Head Lice

    phase 3 small molecule completed

    1 trial

  8. Genotype-guided dosingTaiwan algorithm for warfarin

    China SXT Pharmaceuticals

    Stroke

    phase 3 gene therapy completed

    1 trial

  9. Giapreza 2.5 mg/ml concentrate for solution for infusion, SODIUM CHLORIDE SOLUTION 0.9%

    PAION Pharma GmbH

    refractory hypotension in distributive shock

    phase 3 small molecule active

    1 trial

  10. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis Ophthalmics Europe

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  11. Gilteritinib

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  12. Ginkgo Diterpene Lactone Meglumine Injection

    INTEGRATED BIOPHARMA INC

    Ischemic Stroke

    phase 3 small molecule active

    1 trial

  13. Ginkgo diterpene lactone meglumine injection

    INTEGRATED BIOPHARMA INC

    Ischemic Stroke, Acute

    phase 3 small molecule active

    1 trial

  14. Givinostat 50 mg capsules, RIVAROXABAN , ACETYLSALICYLIC ACID , Givinostat 100 mg capsules, HYDROXYCARBAMIDE, ENOXAPARIN , -, Givinostat 75 mg capsules, DABIGATRAN ETEXILATE

    Italfarmaco S.p.A.

    JAK2V617F-positive high-risk Polycythemia Vera

    phase 3 small molecule active

    1 trial

  15. Givosiran

    Alnylam Netherlands B.V.

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

  16. Glatiramer Acetate

    Teva Pharma GmbH

    Optic Neuritis

    phase 3 small molecule completed

    1 trial

  17. Glatiramer Acetate (DB)

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  18. Glatiramer Acetate (GA) 40 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  19. Glatiramer Acetate 20 mg/0.5 mL

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  20. Glatiramer acetate (GA)

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  21. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  22. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short bowel syndrome

    phase 3 small molecule active

    1 trial

  23. Glepaglutide 20.0 mg/mL, Glepaglutide Placebo

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  24. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources